DMII (Drugs Made In America Acquisition II) EV-to-OCF: -578.66 (As of Jul. 11, 2026)

Drugs Made In America Acquisition II  (NAS:DMII) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Drugs Made In America Acquisition II's PE Ratio (TTM) for today is calculated as:

Drugs Made In America Acquisition II's share price for today is $10.10.
Drugs Made In America Acquisition II's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.229.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Drugs Made In America Acquisition II EV-to-OCF Related Terms

The historical data trend for Drugs Made In America Acquisition II's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II EV-to-OCF Chart

DMII vs BCSS, EVAC, CEPF: EV-to-OCF Comparison

For the Shell Companies subindustry, Drugs Made In America Acquisition II's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drugs Made In America Acquisition II EV-to-OCF vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Drugs Made In America Acquisition II's EV-to-OCF falls into.

Drugs Made In America Acquisition II EV-to-OCF Calculation

Drugs Made In America Acquisition II's EV-to-OCF for today is calculated as:

Drugs Made In America Acquisition II's current Enterprise Value is $643.47 Mil.
Drugs Made In America Acquisition II's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II Business Description